NUOBIKAN(02635.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
NUOBIKAN
02635.HK
Nuobikan Artificial Intelligence Technology (Chengdu) Co., Ltd. designs and develops an industrial application of advanced technologies including AI and digital twins that target areas of transportation, energy, and urban management. The company provides integrated software and hardware solutions adopting comprehensive AI industry models for monitoring, inspection and maintenance purposes. It also offers rail transit for transportation solution business, electricity for energy solution business, and urban management solution business.
586.52 B
02635.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nuobikan AI Ends IPO Stabilization With No Over-Allotment as Public Float Compliance Confirmed

    Nuobikan Artificial Intelligence Technology (Chengdu) Co. Ltd. has concluded its IPO stabilization period as of January 17, 2026, confirming compliance with Hong Kong Stock Exchange's public float requirements. The company reported no over-allocation in the international tranche and no stabilizing actions were taken during the period. The over-allotment option has lapsed, ensuring no additional H shares will be issued. Nuobikan operates in the AI technology sector and is listed in Hong Kong as a Class H share issuer.

    Tip Ranks·
    HK
    02635
    +3.88%
    Tip Ranks·
    HK
    02635
    +3.88%

    Top 10 HK Stock Losers (1.19)

    REFIRE(02570) fell 15.24%, with a trading turnover 137.8 Million HKD, and a year-to-date fell 6.9%. COUNTRY GARDEN(02007) fell 14.47%, with a trading turnover 377.4 Million HKD, and a year-to-date fell 21.7%. DEEWIN(02418) fell 14.01%, with a trading turnover 8.7 Million HKD, and a year-to-date fell 72.1%.

    Top Gainers & Losers·
    HK
    02570
    +1.21%
    HK
    02007
    -6.90%
    HK
    02418
    +19.28%
    Top Gainers & Losers·
    HK
    02570
    +1.21%
    HK
    02007
    -6.90%
    HK
    02418
    +19.28%

    Top 10 HK Stock Losers (1.7)

    DEEWIN(02418) fell 14.48%, with a trading turnover 10.0 Million HKD, and a year-to-date fell 35%. CHINA CHUNLAI(01969) fell 10.36%, with a trading turnover 17.4 Million HKD, and a year-to-date fell 9.9%. NUOBIKAN(02635) fell 10.05%, with a trading turnover 42.3 Million HKD, and a year-to-date rose 2.4%.

    Top Gainers & Losers·
    HK
    02418
    +19.28%
    HK
    01969
    +2.24%
    HK
    02635
    +3.88%
    Top Gainers & Losers·
    HK
    02418
    +19.28%
    HK
    01969
    +2.24%
    HK
    02635
    +3.88%

    Morning Trend | NUOBIKAN main force continues to push higher, small-cap volatility intensifies

    On January 6th, NUOBIKAN (2635.HK) strengthened again, with the ChiNext hot themes heating up, and small-cap stocks becoming a temporary target for funds. During the trading session, the main force continuously pushed up the stock price, approaching historical highs, creating a significant short-term trading atmosphere. The company actively disclosed new drug research and development progress, stimulating investor sentiment in the market. The technical trend reflects characteristics of main force control, but short-term high signals have already been released, and after a significant increase in trading volume and turnover, market sustainability remains uncertain. Recently, the overall volatility of the sector has been frequent, and the rising chasing sentiment has also brought potential profit-taking pressure. Currently, many small-cap themes are experiencing rapid in-and-out operations by funds, with noticeable intraday fluctuations. In the future, it is necessary to strengthen risk management and pay attention to the impact of changes in fund flows on market structure in scenarios of severe volatility. Investors are advised to focus on tracking the company's industrial catalysts, the rhythm of clinical data disclosures, and sector rotation changes, avoiding chasing high prices and excessive concentration of positions

    Technical Forecast·
    HK
    02635
    +3.88%
    Technical Forecast·
    HK
    02635
    +3.88%

    Morning Trend | NUOBIKAN sees increased volume and stops falling, sparking interest in innovative growth concepts?

    On January 5th, NUOBIKAN (2635.HK) rebounded from a low level under capital attention. Pharmaceutical growth stocks have been positively influenced by frequent policy benefits, and the market's main line has returned to the growth sector. During the trading session, NUOBIKAN saw a surge in volume, with market sentiment primarily bullish and speculative enthusiasm remaining high. As an innovative newcomer straddling the biomedical and technology services sectors, NUOBIKAN's drug development progress and emerging projects have garnered widespread market attention, with some cutting-edge pipelines entering late-stage trials, and the group's innovative strength closely monitored by external institutions. The intensity of main capital intervention increased during the session, attracting active speculative funds due to its new stock attributes, resulting in significant short-term gains. Technically, this is reflected in a price rebound from a decline, with notable structural rotation characteristics. The MACD shows a bottom divergence and a volume breakout, with the daily structure continuously improving, and the moving average system quickly diverging after a brief convergence. After a high point in the intraday trend, momentum slightly retreated, and the atmosphere of observation and divergence further intensified. The capital realization is manifested by larger intraday fluctuations, and investors need to be cautious of the pullback risks brought by high valuations. Attention should still be paid to sector rotation and fluctuations influenced by news. Under the circumstances of main capital realizing benefits, policy adjustments, or marginal weakening of news, the trend may face pressure and correction. It is recommended to focus on the pharmaceutical growth main line, reasonably control positions, and pay attention to changes in capital trends and industry directions at any time

    Technical Forecast·
    HK
    02635
    +3.88%
    Technical Forecast·
    HK
    02635
    +3.88%
    © 2026 Longbridge｜Disclaimer